Eli Lilly and (NYSE: LLY) and Shire Viropharma (NASDAQ:VPHM) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, earnings, dividends, valuation, profitability and institutional ownership.

Earnings and Valuation

This table compares Eli Lilly and and Shire Viropharma’s gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio EBITDA Earnings Per Share Price/Earnings Ratio
Eli Lilly and $22.00 billion 3.98 $5.99 billion $2.31 35.90
Shire Viropharma N/A N/A N/A N/A N/A

Eli Lilly and has higher revenue and earnings than Shire Viropharma.

Insider & Institutional Ownership

75.8% of Eli Lilly and shares are owned by institutional investors. 0.2% of Eli Lilly and shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.


Eli Lilly and pays an annual dividend of $2.08 per share and has a dividend yield of 2.5%. Shire Viropharma does not pay a dividend. Eli Lilly and pays out 90.0% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Shire Viropharma has increased its dividend for 2 consecutive years.


This table compares Eli Lilly and and Shire Viropharma’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Eli Lilly and 11.12% 28.71% 10.74%
Shire Viropharma N/A N/A N/A

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Eli Lilly and and Shire Viropharma, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Eli Lilly and 1 6 11 0 2.56
Shire Viropharma 0 0 0 0 N/A

Eli Lilly and currently has a consensus price target of $88.94, suggesting a potential upside of 7.26%. Given Eli Lilly and’s higher probable upside, equities research analysts clearly believe Eli Lilly and is more favorable than Shire Viropharma.


Eli Lilly and beats Shire Viropharma on 9 of the 11 factors compared between the two stocks.

About Eli Lilly and

Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists. Its animal health business segment operates through the Company’s Elanco division, which develops, manufactures and markets products for both food animals and companion animals. The Company’s human pharmaceutical products include endocrinology products, neuroscience products, oncology products, immunology products and cardiovascular products. The Company’s animal health products segment includes products for food animals and products for companion animals. As of December 31, 2016, the Company manufactured and distributed its products through facilities in the United States, Puerto Rico and 14 other countries.

About Shire Viropharma

ViroPharma Incorporated (ViroPharma) is biotechnology company. The Company is engaged in the development and commercialization of solutions for physician specialists to address unmet medical needs of patients living with diseases that have few if any clinical therapeutic options including therapeutics for rare and orphan diseases. Its product development portfolio is focused on four programs: inryze (C1 esterase inhibitor [human]) for management of hereditary angioedema, maribavir for cytomegalovirus (CMV) infection, VP 20621 for the management of C. difficile-associated diarrhea (CDAD) and VP20629, which the Company expects to develop for the treatment of Friedreich’s Ataxia. Its product development portfolio is focused on: C1 esterase inhibitor [human], maribavir for cytomegalovirus (CMV) infection, VP20621 (prevention of recurrent CDAD) and VP20629 (treatment of Friedreich’s Ataxia). On January 23, 2014, Shire Plc completed tender offer for 79.5% of ViroPharma Inc.

Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.